Move marks commitment to leading the frontier of AI-driven innovation and simulation in life sciences, company says.
InSilicoTrials revealed that it has officially hired Mark Lovern to be its new chief platform officer. In his new role, Lovern will focus on combining his scientific knowledge with artificial intelligence (AI), machine learning (ML) and simulation technologies, along with an in-depth understanding of regulatory science, to drive the development of the InSilicoTrials.com platform and position it as a catalyst for hyper-accelerating life science R&D.
"Mark's extensive experience and mastery in model-informed drug development align seamlessly with our vision of revolutionizing the life sciences industry," said Luca Emili, CEO, InSilicoTrials, in a company press release. "His prior achievements, combined with our groundbreaking AI and simulations platform, will surely take our capabilities to unprecedented heights.”
Reference: Mark Lovern Joins InSilicoTrials as Chief Platform Officer. PR Newswire. October 17, 2023. Accessed October 19, 2023. https://www.prnewswire.com/news-releases/mark-lovern-joins-insilicotrials-as-chief-platform-officer-301958909.html
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.